研究業績

2026年

論文

• "Manufacturer-Perceived Development and Market-Entry Risks Associated with Discontinuation and Non-launch of Generic Medicines in Japan: A Cross-Sectional Survey of Marketing Authorization Holders "
  Hiroaki Mamiya, Harumi Tagoku, Ken-ichi Izutsu
  Pharmaceutical Medicine (2026).

  • DOI: 10.1007/s40290-026-00636-8
• "Critical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Priorities "
  Ken-ichi Izutsu, Shoto Sasaki, Rin Kondo, Karen Namiki, Hideaki Uzawa, Hiroaki Mamiya
  Biological and Pharmaceutical Bulletin (2026).

  • DOI: 10.1248/bpb.b26-00220
• "Effect of the Regional Quota System on the Spatial Distribution of Physicians in Japan: A Spatial Statistical and Interrupted Time-Series Analysis"
  Akihisa Nakamura, Hiroaki Mamiya, Kurumi Takezawa, Eiji Satoh, Megumi Sakamoto, Kazuhiko Kotani
  The Tohoku Journal of Experimental Medicine (2026).

  • DOI: https://doi.org/10.1620/tjem.2026.J083
• "From incident response to system design: Japan’s 2025 PMD Act drug-shortage reform"
  Hiroaki Mamiya, Eri Oya, Daichi Mitani
  Health Policy (2026).

  • DOI: 10.1016/j.healthpol.2026.105725
• "病院情報システムに必要な医薬品情報とは 医療用医薬品とOTC医薬品に関する医療従事者への調査 "
  池田 和之, 土屋 文人, 間宮 弘晃
  (2026).
• "Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round"
  Hägg A, Wood R, Mochizuki AL, et al
  Stem Cell Reports (2026).

  • DOI: https://doi.org/10.1016/j.stemcr.2026.102857
• "Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan"
  Mamiya, Hiroaki, Toshiki Fukasawa, and Koji Kawakami
  Journal of Pharmaceutical Policy and Practice 19, 1 (2026).

  • DOI: 10.1080/20523211.2026.2633832.

総説／雑誌記事

• "医薬品の安定供給に関する課題と法改正 ―政策経緯と構造的要因の解明―"
  大矢 恵理，間宮 弘晃，三谷 大地
  医薬品医療機器レギュラトリーサイエンス 57, 1, 39-52 (2026).

  • DOI: https://doi.org/10.51018/pmdrs.57.1_39